Table 4 Reported culprits of Stevens-Johnson syndrome according to drug category

Total number of patients with reported Stevens-Johnson syndrome

1706

Drug class/name

 Anti-infectives, n (%)

735 (43.1)

 Beta-lactams, n (%)

348 (20.4)

 Sulphonamides, n (%)

81 (4.7)

 Tetracyclines, n (%)

70 (4.1)

 Quinolones, n (%)

64 (3.8)

 Macrolides, n (%)

50 (2.9)

 Anti-mycobacterials, n (%)

31 (1.8)

 Anti-protozoals, n (%)

22 (1.3)

 Aminoglycosides, n (%)

21 (1.2)

 Anti-virals, n (%)

14 (0.8)

 Glycopeptides, n (%)

12 (0.7)

 Anti-fungals, n (%)

8 (0.5)

 Lincosamides, n (%)

7 (0.4)

 Other anti-infectives, n (%)

7 (0.4)

 Nervous system, n (%)

390 (22.9)

 Musculoskeletal system, n (%)

348 (20.4)

 Cardiovascular system, n (%)

55 (3.2)

 Gastrointestinal system, n (%)

39 (2.3)

 Respiratory system, n (%)

33 (1.9)

 Anaesthesia, n (%)

24 (1.4)

 Immune system and malignant diseases, n (%)

16 (0.9)

 Ear, nose and throat, n (%)

8 (0.5)

 Eye, n (%)

7 (0.4)

 Skin, n (%)

5 (0.3)

 Blood and nutrition, n (%)

5 (0.3)

 Genito-urinary system, n (%)

4 (0.2)

 Vaccines, n (%)

2 (0.1)

 Endocrine system, n (%)

2 (0.1)

 Unknown drug culprit, n (%)

33 (1.9)